Sanofi Bags EU Approvals But Fumes At Regulator
Green Lights For Nexviadyme And Xenpozyme
Although Nexviadyme has been approved, the French group is still unhappy about the EMA's view that the Pompe disease therapy should not be classified as a new active substance.
You may also be interested in...
The French drugmaker is looking to consolidate its dominance of the Pompe disease area by filing its successor to Myozyme in Europe, but Amicus Therapeutics' potential rival AT-GAA is on the horizon.
The French firm's lead microbiome therapy has been on clinical hold in the US for a year and continuing concerns about MaaT's 'pooling' approach (mixing donations from multiple donors) suggests the wait to restart trials will not be a short one.
Faced with a scarily short cash runway and an ongoing expensive mid-stage study of an allogeneic cell therapy for the treatment of delayed-union bone fractures, Bone Therapeutics has found a saviour in France's Medsenic.